Jan, 29 2024

探索突破：急性骨髓性白血病藥物的進展與創新，增強治療策略

秘魯急性骨髓性白血病 (AML) 藥物市場受到動態醫療實踐和藥物創新的影響。 AML 是一種血癌，需要針對性藥物開發。 AML 藥物（包括化療和標靶療法）可對抗骨髓中異常的髓細胞生長。它們的目的是消除白血病細胞，恢復正常的血球生成，並控制症狀。治療包括藥物組合、個人化治療和幹細胞移植，反映了 AML 藥物開發的持續進步。

訪問完整報告 @ https://www.databridgemarketresearch.com/reports/peru-acute-myeloid-leukemia-drugs-market

Data Bridge Market Research 分析，秘魯急性髓細胞白血病藥物市場在 2022 年至 2029 年的預測期內將以 6.5% 的複合年增長率增長。持續的醫生教育計劃至關重要，它為醫療保健專業人員提供有關最新急性髓細胞白血病治療的見解，積極影響處方決策，並改善患者護理結果。

研究的主要發現

臨床試驗的增加預計將推動市場成長率

1995 年至 2019 年，秘魯的臨床試驗（尤其是腫瘤學試驗）數量激增，其中 23.5% 用於腫瘤學研究，顯示研究前景十分廣闊。這種成長趨勢顯示人們致力於探索新的療法和治療方法。這些試驗中觀察到的多樣化特徵，例如不同的方法和創新的干預措施，有助於科學知識並增強發現和批准新的急性髓性白血病藥物的潛力。這種充滿活力的研究環境促進了持續的進步，推動了市場的成長和發展。

報告範圍和市場細分

報告指標

細節

預測期

2022年至2029年

基準年

2021

歷史歲月

2020（可自訂為2014-2019）

涵蓋的領域

亞型（M0（未分化急性骨髓性白血病）、M1（成熟度最低的急性骨髓性白血病）、M2（成熟度最高的急性骨髓性白血病）、M3（急性早幼粒細胞白血病(APL)）、M4（急性單核細胞白血病）、M5（急性單核細胞白血病）、M6（急性紅血球白血病）、M7（急性巨核細胞白血病）、藥物（化療、標靶治療、免疫治療）、藥物類型（品牌藥和仿製藥）、給藥途徑（腸外、口服和其他）、人群類型（老年人、成人和兒童）、最終用戶（醫院、專科診所、門診中心和其他）、分銷渠道（直接招標、醫院藥房、零售藥房、網上藥房和其他）

涵蓋的市場參與者

輝瑞公司（美國）、默克夏普和多姆公司（默克公司的子公司）（美國）、楊森製藥公司（強生服務公司的子公司）（美國）、諾華公司（瑞士）、費森尤斯卡比公司（德國）、羅氏公司（瑞士）、艾伯維公司（美國）、德國工業製藥公司（英國）、德國）、羅氏公司（瑞士）、艾伯維公司（美國）、德國工業製藥公司（英國）、英國）、英國工業有限公司（以色列工業有限公司）

報告涵蓋的數據點

除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察之外，Data Bridge Market Research 策劃的市場報告還包括深度專家分析、患者流行病學、管道分析、定價分析和監管框架。

細分分析：

秘魯急性髓細胞白血病藥物市場根據子類型、藥物、藥物類型、給藥途徑、人群類型、最終用戶和分銷管道進行細分。

根據亞型途徑，秘魯急性骨髓性白血病藥物市場細分為 M0（未分化急性髓細胞白血病）、M1（成熟度最低的急性骨髓性白血病）、M2（成熟度高的急性髓細胞白血病）、M3（急性早幼粒細胞白血病 (APL)）、M4（急性粒單核細胞白血病）、M5（急性早幼粒細胞白血病 (APL)）、M4（急性粒單核細胞白血病）、M5（急性單核細胞白血病）、M6（急性單核細胞性白血病）

根據藥物，秘魯急性骨髓性白血病藥物市場分為化療、標靶治療、免疫治療等

根據藥物類型，秘魯急性骨髓性白血病藥物市場分為品牌藥和仿製藥

根據給藥途徑，秘魯急性骨髓性白血病藥物市場分為口服、腸外給藥和其他

根據人口類型，秘魯急性骨髓性白血病藥物市場分為兒科、成人和老年

根據最終用戶，秘魯急性骨髓性白血病藥物市場分為醫院、專科診所、門診中心和其他

根據分銷管道，秘魯急性髓系白血病藥物市場分為直銷、醫院藥房、零售藥房、網路藥房和其他

主要參與者

Data Bridge Market Research 認為以下公司是秘魯急性髓性白血病藥物市場的主要參與者，它們是 F. Hoffmann-La Roche Ltd（瑞士）、Abbvie Inc（美國）、AstraZeneca（英國）、Boehringer Ingelheim International GmbH（德國）、Sun Pharmaceutical Industries Ltd.（印度）、Teva Pharmace Ingelheim International Ltd.（以色列）

市場發展

2022年8月，第一三共向日本厚生勞動省（MHLW）提交了補充新藥申請（sNDA）。該申請尋求批准將奎扎替尼與標準阿糖胞苷、蒽環類誘導和標準阿糖胞苷鞏固化療合併使用。預期用途是治療日本新診斷的 FLT3-ITD 陽性急性骨髓性白血病 (AML) 成年患者

2022年6月，基石藥廠的合作夥伴施維雅公司取得了重要的里程碑，TIBSOVO（ivosidenib片）獲得美國食品藥物管理局（FDA）的批准。此次批准與阿扎胞苷聯合使用，標誌著 75 歲或以上新診斷為 IDH1 突變急性髓系白血病 (AML) 或患有阻礙強化誘導化療的合併症的成年人取得了突破性進展。 TIBSOVO 代表了針對特定 AML 患者群體癌症代謝的開創性療法

2021 年 6 月，百時美施貴寶獲得歐盟委員會批准 Onureg，這是一種用於治療成人急性骨髓性白血病的第一線口服維持療法。這一里程碑確保了在美國、歐洲和南美的上市後批准。隨著 Onureg 預期的正面影響（包括增加銷售額和產品收入），厄瓜多爾和秘魯的 AML 藥物市場有望實現成長，從而加強該公司致力於推進白血病治療的承諾

2020 年 10 月，艾伯維公司 (AbbVie Inc.) 獲得 FDA 批准將 Venclexta 與阿扎胞苷、地西他濱或 LDAC 聯合用於治療 75 歲及以上成人新診斷的 AML。這項批准使得 AbbVie 擴大了在北美、拉丁美洲和歐洲的腫瘤產品線，以滿足無法接受強化化療的患者的需求。 Venclexta 上市後獲準進一步擴大了核准地區 AML 的治療選擇

有關秘魯急性髓系白血病藥物市場報告的更多詳細信息，請點擊此處 - https://www.databridgemarketresearch.com/reports/peru-acute-myeloid-leukemia-drugs-market

CHOOSE LICENCE TYPE

Enterprise User 7000
Single User 4800
DBMR Factbook 3000
DBMR Prime 8000
DBMR Nucleus 12000

Buy Now

Advance Formative Research Customization Request for bulk Reports

Latest Press Release

Expanding FPC Adoption in Automotive and Medical Electronics is Expected to Drive the Market

Rising Prevalence of Chronic Diseases is the Driving Factor in the Market

Growing Focus on Nuclear Fusion Research Drives Soft Magnetic Material Demand

Growing Demand for Packaged Beverages, Pharmaceuticals, and Personal Care Products

Rising Demand for Packaged and Convenience Food Products, Supported by Rapid Urbanization and Lifestyle Changes, is Driving the Growth of the Global Flexible Packaging Market

Rising Demand for Antioxidants in Processed Food and Beverages is the Driving Factor in the Market

VIEW ALL

Client Testimonials

Claudio Rondena

Group Business Development & Strategic Marketing Director,
C.O.C Farmaceutici SRL

"This morning we were involved in the first part, the data presentation of MKT analysis, selected abstract from your work. The board team was really impressed and very appreciated, as well."

David Manning - Thermo Fisher Scientific

Director, Global Strategic Accounts,

Dear Ricky,
I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.

Manager - Market Analytics,

Uriah D. Avila - Zeus Polymer Solutions

Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.

Business Development Manager,

(Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC

DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.

Business Intelligence and Analytics,

Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Competition Analyst,

Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Marketing Director,

Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

COO,

A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Marketing Director,

Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Product manager,

Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Investor relations,

GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Market Analyst,

Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Andrew - Senior Global Marketing Manager,

Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Amarildo - Manager, Global Strategic Alignment

MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Tor Hammer

Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Tommaso Finocchiaro

Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Yuki Kopyl (Asian Business Development Department)

UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future